182 related articles for article (PubMed ID: 15716710)
1. Transforming growth factor beta1 and additional renoprotective effect of combination ACE inhibitor and angiotensin II receptor blocker in hypertensive subjects with minor renal abnormalities: a 24-week randomized controlled trial.
Scaglione R; Argano C; Corrao S; Di Chiara T; Licata A; Licata G
J Hypertens; 2005 Mar; 23(3):657-64. PubMed ID: 15716710
[TBL] [Abstract][Full Text] [Related]
2. Effect of low-dose dual blockade of renin-angiotensin system on urinary TGF-beta in type 2 diabetic patients with advanced kidney disease.
Song JH; Cha SH; Lee HJ; Lee SW; Park GH; Lee SW; Kim MJ
Nephrol Dial Transplant; 2006 Mar; 21(3):683-9. PubMed ID: 16330466
[TBL] [Abstract][Full Text] [Related]
3. The effects of dual blockade of the renin-angiotensin system on urinary protein and transforming growth factor-beta excretion in 2 groups of patients with IgA and diabetic nephropathy.
Song JH; Lee SW; Suh JH; Kim ES; Hong SB; Kim KA; Kim MJ
Clin Nephrol; 2003 Nov; 60(5):318-26. PubMed ID: 14640237
[TBL] [Abstract][Full Text] [Related]
4. Low-dose dual blockade of the renin-angiotensin system improves tubular status in non-diabetic proteinuric patients.
Renke M; Tylicki L; Rutkowski P; Wojnarowski K; Lysiak-Szydlowska W; Rutkowski B
Scand J Urol Nephrol; 2005; 39(6):511-7. PubMed ID: 16303729
[TBL] [Abstract][Full Text] [Related]
5. Add-on angiotensin II receptor blockade lowers urinary transforming growth factor-beta levels.
Agarwal R; Siva S; Dunn SR; Sharma K
Am J Kidney Dis; 2002 Mar; 39(3):486-92. PubMed ID: 11877567
[TBL] [Abstract][Full Text] [Related]
6. Central obesity and hypertensive renal disease: association between higher levels of BMI, circulating transforming growth factor beta1 and urinary albumin excretion.
Scaglione R; Argano C; di Chiara T; Colomba D; Parrinello G; Corrao S; Avellone G; Licata G
Blood Press; 2003; 12(5-6):269-76. PubMed ID: 14763657
[TBL] [Abstract][Full Text] [Related]
7. Long-term comparison of losartan and enalapril on kidney function in hypertensive type 2 diabetics with early nephropathy.
Lacourcière Y; Bélanger A; Godin C; Hallé JP; Ross S; Wright N; Marion J
Kidney Int; 2000 Aug; 58(2):762-9. PubMed ID: 10916100
[TBL] [Abstract][Full Text] [Related]
8. Persistent effects on blood pressure and renal function of perindopril alone or combined with losartan in Lyon hypertensive rats.
Naelten G; Liu KL; Chapuis B; Lo M
Am J Hypertens; 2005 May; 18(5 Pt 1):699-706. PubMed ID: 15882554
[TBL] [Abstract][Full Text] [Related]
9. Renin-angiotensin system blockade prevents the increase in plasma transforming growth factor beta 1, and reduces proteinuria and kidney hypertrophy in the streptozotocin-diabetic rat.
Erman A; Veksler S; Gafter U; Boner G; Wittenberg C; van Dijk DJ
J Renin Angiotensin Aldosterone Syst; 2004 Sep; 5(3):146-51. PubMed ID: 15526251
[TBL] [Abstract][Full Text] [Related]
10. Add-on angiotensin receptor blockade with maximized ACE inhibition.
Agarwal R
Kidney Int; 2001 Jun; 59(6):2282-9. PubMed ID: 11380832
[TBL] [Abstract][Full Text] [Related]
11. Increased gene expression of components of the renin-angiotensin system in glomeruli of genetically hypertensive rats.
Obata J; Nakamura T; Takano H; Naito A; Kimura H; Yoshida Y; Shimizu F; Guo DF; Inagami T
J Hypertens; 2000 Sep; 18(9):1247-55. PubMed ID: 10994756
[TBL] [Abstract][Full Text] [Related]
12. Effect of losartan on TGF-beta1 and urinary albumin excretion in patients with type 2 diabetes mellitus and microalbuminuria.
Esmatjes E; Flores L; Iñigo P; Lario S; Ruilope LM; Campistol JM
Nephrol Dial Transplant; 2001; 16 Suppl 1():90-3. PubMed ID: 11369831
[TBL] [Abstract][Full Text] [Related]
13. Long-term effects of angiotensin-converting enzyme inhibition and metabolic control in hypertensive type 2 diabetic patients.
Chan JC; Ko GT; Leung DH; Cheung RC; Cheung MY; So WY; Swaminathan R; Nicholls MG; Critchley JA; Cockram CS
Kidney Int; 2000 Feb; 57(2):590-600. PubMed ID: 10652036
[TBL] [Abstract][Full Text] [Related]
14. Renal hemodynamics in essential hypertensives treated with losartan.
Erley CM; Bader B; Scheu M; Wolf S; Braun N; Risler T
Clin Nephrol; 1995 Jan; 43 Suppl 1():S8-11. PubMed ID: 7781206
[TBL] [Abstract][Full Text] [Related]
15. Relationship between transforming growth factor beta1 and progression of hypertensive renal disease.
Scaglione R; Argano C; Parrinello G; Colomba D; Di Chiara T; Ferrante A; Di Garbo V; Avellone G; Licata G
J Hum Hypertens; 2002 Sep; 16(9):641-5. PubMed ID: 12214261
[TBL] [Abstract][Full Text] [Related]
16. Renoprotective effects of angiotensin II receptor blockade in type 1 diabetic patients with diabetic nephropathy.
Andersen S; Tarnow L; Rossing P; Hansen BV; Parving HH
Kidney Int; 2000 Feb; 57(2):601-6. PubMed ID: 10652037
[TBL] [Abstract][Full Text] [Related]
17. Effects of intensified blood-pressure reduction on renal function and albumin excretion in primary hypertension. Addition of felodipine or ramipril to long-term treatment with beta-blockade.
Siewert-Delle A; Ljungman S; Hartford M; Wikstrand J
Am J Hypertens; 1995 Feb; 8(2):113-23. PubMed ID: 7755939
[TBL] [Abstract][Full Text] [Related]
18. Renal effects of long-term leptin infusion and preventive role of losartan treatment in rats.
Gunduz Z; Dursun N; Akgun H; Ozturk F; Okur H; Koc N
Regul Pept; 2005 Dec; 132(1-3):59-66. PubMed ID: 16229907
[TBL] [Abstract][Full Text] [Related]
19. ACE inhibition versus angiotensin type 1 receptor antagonism: differential effects on PAI-1 over time.
Brown NJ; Kumar S; Painter CA; Vaughan DE
Hypertension; 2002 Dec; 40(6):859-65. PubMed ID: 12468570
[TBL] [Abstract][Full Text] [Related]
20. Combined therapy of cilazapril and losartan has no additive effects in ameliorating adriamycin-induced glomerulopathy.
Kim HJ; Ryu JH; Han SW; Park IK; Paik SS; Park MH; Paik DJ; Chung HS; Kim SW; Lee JU
Nephron Physiol; 2004; 97(4):p58-65. PubMed ID: 15331931
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
